Download
1 / 5
50 likes | 216 Views
Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., notes that CAR-T therapy can produce serious toxic reactions, the worst of which is a cytokine release syndrome that causes symptoms similar to those of septic shock.
E N D
Dr. Michael Har-NoyCreates The Unique Mirror EffectTM Technology
Dr. Michael Har-Noy Discusses AlloStimTM In The Treatment Of HIV In January of last year, Dr. Michael Har-Noy administered AlloStimTM to a single test patient with HIV. Dr. Michael Har-Noy theorized that AlloStimTM might cause the patient’s immune system to flush out the reservoir of HIV and create a potential cure. After multiple doses of AlloStimTM, the patient’s viral load is down and CD4 count is at a record high.
Dr. Michael Har-Noy Compares AlloStimTM to Checkpoint Blockade Therapy Dr. Michael Har-Noy of Immunovative Therapies, Ltd. says that checkpoint blockade drugs block molecules used by cancer cells to hide from the immune system. Yervoy and Opdivo are examples of such drugs. Dr. Michael Har-Noy notes, however, that checkpoint blockade drugs work only if there is an existing intact immune response and are therefore effective in a minority of tumors. Immunovative Therapies, Ltd.’s AlloStimTM, says Dr. Michael Har-Noy, creates its own immune response and may therefore be potentially effective in all kinds of tumors.
Dr. Michael Har-Noy Discusses Upcoming Pivotal Trial In Colorectal Cancer Dr. Michael Har-Noy is planning to conduct a pivotal Phase II/III randomized trial of AlloStimTM in the treatment of KRAS gene positive metastatic colon cancer. Dr. Michael Har-Noy says there is no approved third line treatment option for patients with this disease. Successful completion of this trial would lead to marketing approval of AlloStimTM. Dr. Michael Har-Noy plans to conduct the trial in Thailand as well as the United States.
